TY - JOUR
KW - Adolescent
KW - Alcohol-Related Disorders/drug therapy/epidemiology
KW - Analgesics, Opioid/administration & dosage/adverse effects/therapeutic use
KW - Buprenorphine/administration & dosage/therapeutic use
KW - Child
KW - Comorbidity
KW - Delivery, Obstetric/methods
KW - Female
KW - Humans
KW - Infant, Newborn
KW - Methadone/administration & dosage/therapeutic use
KW - Neonatal Abstinence Syndrome/drug therapy/prevention & control
KW - Opiate Substitution Treatment/methods
KW - Opioid-Related Disorders/diagnosis/drug therapy/epidemiology
KW - Pain Management/methods
KW - Pregnancy
KW - Pregnancy Complications/diagnosis/drug therapy/epidemiology
KW - Prenatal Care/methods/organization & administration
KW - Prenatal Exposure Delayed Effects
KW - Prescription Drugs/adverse effects
KW - Self Medication
KW - Substance Withdrawal Syndrome/prevention & control
KW - United States/epidemiology
AU - J. L. Young
AU - P. R. Martin
A1 - 
AB - Opioid dependence in the setting of pregnancy provides a distinct set of challenges for providers. Treatment plans must take into consideration psychiatric and medical comorbidities while balancing risks and benefits for the maternal-fetal dyad. Treatment is best offered through a comprehensive treatment program designed to effectively deliver opioid agonist maintenance treatment along with psychosocial and obstetric care. As misuse of prescription analgesics increases in the United States, identification of the problem in pregnancy will become more important because this misuse is expected to lead to an increased prevalence of opioid dependence in pregnancy. Buprenorphine as maintenance treatment of opioid dependence during pregnancy has promise and may offer some benefits, but more research is needed, especially regarding induction of actively addicted women during pregnancy. For the present, methadone maintenance remains the standard of care for agonist treatment of opioid dependence in pregnancy against which other treatments must be compared.
BT - The Psychiatric clinics of North America
C5 - Opioids & Substance Use
CP - 2
CY - United States
DO - 10.1016/j.psc.2012.03.008
IS - 2
JF - The Psychiatric clinics of North America
N2 - Opioid dependence in the setting of pregnancy provides a distinct set of challenges for providers. Treatment plans must take into consideration psychiatric and medical comorbidities while balancing risks and benefits for the maternal-fetal dyad. Treatment is best offered through a comprehensive treatment program designed to effectively deliver opioid agonist maintenance treatment along with psychosocial and obstetric care. As misuse of prescription analgesics increases in the United States, identification of the problem in pregnancy will become more important because this misuse is expected to lead to an increased prevalence of opioid dependence in pregnancy. Buprenorphine as maintenance treatment of opioid dependence during pregnancy has promise and may offer some benefits, but more research is needed, especially regarding induction of actively addicted women during pregnancy. For the present, methadone maintenance remains the standard of care for agonist treatment of opioid dependence in pregnancy against which other treatments must be compared.
PP - United States
PY - 2012
SN - 1558-3147; 0193-953X
SP - 441
EP - 460
EP - 
T1 - Treatment of opioid dependence in the setting of pregnancy
T2 - The Psychiatric clinics of North America
TI - Treatment of opioid dependence in the setting of pregnancy
U1 - Opioids & Substance Use
U2 - 22640765
U3 - 10.1016/j.psc.2012.03.008
VL - 35
VO - 1558-3147; 0193-953X
Y1 - 2012
ER -